Comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% imiquimod cream in the treatment of actinic keratosis

Journal of Dermatological Treatment

Volumn 19, Issue 3, 2008, Pages 159-163

  Kose, Osman ^a   Koc, Erol ^a   Erbil, A Hakan ^a   Caliskan, Ercan ^a   Kurumlu, Zafer ^a  

^a GULHANE SCHOOL OF MEDICINE   (Turkey)

Author keywords

Actinic keratosis; Diclofenac; Imiquimod; Topical therapy

Indexed keywords

ACTINOMA; DICLOFENAC; HYALURONIC ACID; IMIQUIMOD;

ACTINIC KERATOSIS; ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRY SKIN; ERYTHEMA; FEMALE; HUMAN; MALE; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SCORING SYSTEM; SKIN CRUSTING; SKIN MANIFESTATION; SKIN SCALING; TREATMENT RESPONSE;

ADJUVANTS, IMMUNOLOGIC; ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; AMINOQUINOLINES; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DRUG ADMINISTRATION SCHEDULE; FACE; FEMALE; GELS; HUMANS; KERATOSIS; MALE; MIDDLE AGED; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; ULTRAVIOLET RAYS;

EID: 45849132060     PISSN: 09546634     EISSN: 14711753     Source Type: Journal    
DOI: 10.1080/09546630701818870     Document Type: Article

References (22)

1. Halpern AC, Hanson LJ. Awareness of knowledge of and attitudes to nonmelanoma skin cancer (NMSC) and actinic keratosis (AK) among physicians. Int J Dermatol. 2004;43:638-42.
2. Del Rosso JQ. New and emerging topical approaches for actinic keratoses. Cutis. 2003;72:273-9.
3. Silapunt S, Goldberg LH, Alam M. Topical and light based treatments for keratoses. Semin Cutan Med Surg. 2003;22:162-70.
4. Miller RL, Gerster JF, Owens ML, Slade HB, Tomai MA. Imiquimod applied topically: A novel immune response modifier and new class of drug. Int J Immunopharmacol. 1999;21:1-14.
5. Rivers JK, McLean DI. An open study to assess the efficacy and safety of topical 3% diclofenac in a 2.5% hyaluronan acid gel for the treatment of actinic keratoses. Arch Dermatol. 1997;133:1239-42.
6. Jarvis B, Figgit DP. Topical 3% diclofenac in a 2.5% hyaluronic acid gel. A review of its use in patients with actinic keratoses. Am J Clin Dermatol. 2003;4:203-13.
7. Lee PK, Harwell WB, Loven KH, Phillips TJ, Whiting DA, Andres KL, et al. Long-term clinical outcomes following treatment of actinic keratosis with imiquimod 5% cream. Dermatol Surg. 2005;31:659-64.
8. De Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratoses. Br J Dermatol. 2007;156:222-30.
9. Peters DC, Faster RH. Diclofenac/hyaluronic acid. Drugs Aging. 1999;14:313-21.
10. Nelson C, Rigel D, Smith S, Swanson N, Wolf J. Phase IV, open-label assessment of the treatment of actinic keratosis with 3% diclofenac sodium topical gel. J Drugs Dermatol. 2004;3:401-7.
11. Rivers JK. Topical 3% diclofenac in 2.5% hyaluronan gel for the treatment of actinic keratoses. Skin Therapy Lett. 2004;9:1-3.
12. Merk HF. Topical diclofenac in the treatment of actinic keratoses. Int J Dermatol. 2007;46:12-18.
13. Tran H, Chen K, Shumack S. Summary of actinic keratosis studies with imiqumod 5% cream. Br J Dermatol. 2003;149(suppl 66):37-9.
14. Falagas ME, Angelousi AG, Peppas G. Imiquimod for the treatment of actinic keratosis: A meta-analysis of randomized controlled trials. J Am Acad Dermatol. 2006;55:537-8.
15. Lebwohl M, Dinehart S, Whiting D, Lee PK, Tawfik N, Jorizzo J, et al. Imiquimod 5% for the treatment of actinic keratosis: Result from two phase III, randomized, double-blind, parallel group, vehicle-controlled trials. J Am Acad Dermatol. 2004;50:714-21.
16. Walker JK, Koenig C. Is imiquimod effective and safe for treatment of actinic keratoses? J Fam Pract. 2003;52:184-5.
17. Pirard D, Vereecken P, Melot C, Heemen M. Three percent diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses: A meta-analysis of the recent studies. Arch Dermatol Res. 2005;297:185-9.
18. Wolf JE, Taylor JR, Tschen E, Kang S. Topical 3.0% diclofenac in 2.5% hyaluronan gel in the treatment of actinic keratoses. Int J Dermatol. 2001;40:709-13.
19. Szeimies RM, Gerritsen MJP, Gupta G, Ortonne JD, Serreri S, Bichel J, et al. Imiquimod 5% cream for the treatment of actinic keratosis: Results from phase III, randomized, double-blind, vehicle-controlled, clinical trials with histology. J Am Acad Dermatol. 2004;51:547-55.
20. Smith SR, Morhenn VB, Piacquado DJ. Bilateral comparison of the efficacy and tolerability of 3% diclofenac sodium gel and 5% fluorouracil cream in the treatment of actinic keratoses of the face and scalp. J Drugs Dermatol. 2006;5:156-9.
21. Darlinton S, Williams G, Neale R, Frost C, Green A. A randomized controlled trial to assess sunscreen application and beta carotene supplementation in the prevention of solar keratoses. Arch Dermatol. 2003;139:451-5.
22. Stockfleth E, Kerl H. Guidelines for the management of actinic keratoses. Eur J Dermatol. 2006;16:599-606.